• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Medtronic CEO: Emerging markets could be safer bet than developing products for the U.S.

Medtronic CEO: Emerging markets could be safer bet than developing products for the U.S.

August 25, 2011 By MassDevice staff

Omar Ishrak

Ishrak

Targeting the growing middle class in China, India and other emerging countries may be “potentially less risky than creating new products for the flat U.S market,” new Medtronic Inc. (NYSE:MDT) CEO Omar Ishrak said in his first shareholders meeting today.

Ishrak, who has been charged with expanding the mission of the world’s largest pure play medical device maker, even as 40 percent of its core businesses experienced negative growth last year, laid out his vision for the second time this week.

The newly minted chief executive revealed his move to reshape the company, first reported by MassDevice, in an email sent to employees last week. The most dramatic moves concern expanding Medtronic’s global footprint by creating eight geographic regions: the U.S., Western Europe/Canada, Latin America, Greater China, Asia (including Japan), India, Middle East/Africa and Central and Eastern Europe.

This morning, Ishrak explained that those moves were necessary in order to reignite growth at the company.

“The biggest long term opportunity will be to meet the needs of billions of people who have no access to healthcare at all,” he said. “The population in emerging markets is tenfold that of developed countries. These statistics are further compounded by the fact that U.S. market is essentially flat…reaching the global middle class opens up opportunities to us beyond anything we’ve ever seen before.”

He added that there was already 200,000 to 300,000 people in the middle class in India who could afford many of Medtronic’s technologies right now and that helping to build the health care infrastructure around those patients could lead to millions more. The same scenario is true in China, where Ishrak said the market could be larger than the U.S. by the end of the decade. Combined with opportunities in Brazil, Russia and other emerging markets he laid out a goal of reaching 25 million patients by 2020.

“Our mission applies to all people,” he said. “It is both our responsibility and our opportunity.”

Ishrak even circled back to his own upbringing in Bangladesh saying that he was “keenly aware” of how people growing up in poor countries are deprived of even the most basic of Medtronic’s technology portfolio, going as far back as MDT-founder Earl Baaken’s first pacemakers.

But while he was looking to the future, Ishrak also continued to hammer Medtronic for its recent performance, saying that the company’s somewhat slow growth was the result of poor execution, quality issues and a sluggish business model.

He said while the company has acquired lots of companies and launched more than 16 new products over the past year, it has failed to capitalize in a meaningful way.

“The number of new products does not have any correlation with growth,” he said. “Our method of selecting and prioritizing our investments has to change.”

He promised to be intimately involved in those processes and to integrate them into the culture of Medtronic.

Ishrak said his vision of crisp execution and a holistic view of the global markets was the only way the company could start to return to the meteoric growth that was once synonymous with the Fridely, Minn.-based medical device giant and its share price.

“I know stock is of concern. The value of our stock is largely the reflection of our performance. When we are able to demonstrate growth the stock market will reward us,” he said. “We need to resist the temptation to blame the markets and begin to adapt. Ultimately, our job is to deliver growth despite whats happening to our markets.”

Filed Under: MassDevice Earnings Roundup, News Well, Wall Street Beat

In case you missed it

  • Boston Scientific to build new plant outside Atlanta
  • NovaXS unveils prototype for smart, needle-free drug delivery device
  • ResMed names Lucile Blaise as new Sleep & Respiratory Care leader
  • SpineX enrolls first patient in spinal neuromodulation technology trial
  • GE Healthcare’s Carescape ventilator battery recall is Class I
  • Cardinal Health starts Zipline drone deliveries of drugs and medical supplies
  • Advanced NanoTherapies closes $7.2M Series A for drug-coated balloon
  • Centerline Biomedical raises $33M Series B
  • How medical device companies are responding to abortion bans
  • Memic completes first robotic-assisted transvaginal hysterectomy procedures with Hominis
  • ‘Multiple disruptions’ slow timeline for Titan Medical’s Enos robotic surgery platform
  • Philips updates on testing results for recalled ventilators
  • Varian wins FDA IDE for Flash radiation therapy
  • Researchers develop wearable robotic exomuscle system
  • Virpax to pursue over-the-counter pathway for topical spray treatment for osteoarthritis pain
  • Inovio names new chief medical officer
  • FDA clears Acutus’ AcQCross system for use with Boston Scientific’s Watchman

RSS From Medical Design & Outsourcing

  • Philips updates on testing results for recalled ventilators
    Royal Philips (NYSE:PHG) says only a small portion of returned respiratory devices displayed the sound abatement foam degradation that sparked a massive recall. Repeated ozone cleaning may have made the problem worse. Those were some of the major takeaways from an update Philips provided today on a comprehensive test and research program it implemented after its… […]
  • ResMed names Lucile Blaise as new Sleep & Respiratory Care leader
    Lucile Blaise will be the new president of ResMed’s Sleep & Respiratory Care business starting July 1, ResMed (NYSE: RMD) said today. She replaces Jim Hollingshead, who became president and CEO of Insulet (Nasdaq:PODD) on June 1. ResMed President and COO Rob Douglas is serving as interim president of the Sleep & Respiratory Care during… […]
  • Cardinal Health starts Zipline drone deliveries of drugs and medical supplies
    Cardinal Health (NYSE: CAH) today started air delivery of pharmaceutical products and medical supplies via Zipline drone in North Carolina. San Francisco-based Zipline won FAA Part 135 air carrier certification for the long-range flights earlier this month. The company flew its first commercial deliveries on June 22 with an initial 16-nautical-mile flight. The flights starting… […]
  • How medical device companies are responding to abortion bans
    Days after the U.S. Supreme Court’s decision to overturn Roe v. Wade’s protection of abortion rights, medical device companies are among those reassuring workers about healthcare access. Corporate communications to employees and the public at large come as trigger laws in nearly half of the states outlaw abortion immediately. Some medtech companies are not using… […]
  • Boston Centerless opens manufacturing plant in Indiana
    Boston Centerless announced today that it opened a second manufacturing plant in Fort Wayne, Indiana. Woburn, Massachusetts-based Boston Centerless said in a news release that the latest expansion for the supplier of precision ground bar materials for close tolerance CNC Swiss machining applications represents continued robust growth in key market segments in the Midwest and… […]
  • Dymax strikes new partnership with Quantum Systems
    Rapid curing materials and equipment manufacturer Dymax today announced a new sales partnership with Quantum Systems. Torrington, Connecticut-based Dymax said in a news release that Quantum, with its offices in Arizona as well as Sonora and Baja, Mexico, will focus its efforts on promoting and supporting the sales of Dymax light-curing solutions to the medical,… […]
  • Researchers develop wearable robotic exomuscle system
    ETH Zurich researchers have redefined the muscle shirt. Marie Georgarakis, a former doctoral student at ETH Zurich’s Sensory Motor Systems Lab, is the creator of the Myoshirt, a wearable, textile robotic device that helps users lift their arms and reach. A motorized cable works like an artificial tendon, directed by sensors and an algorithm to… […]
  • They said it at DeviceTalks Boston
    Medtech insiders convened at DeviceTalks Boston 2022 in May to discuss device design, innovation and trends shaping the industry now and in the years and decades ahead. Here are some of the most quotable insights from panelists and speakers at our live event. And make sure to save the date — and save your seat… […]
  • Summer health technology program brings diverse group of interns to Silicon Valley
    Diversity by Doing HealthTech (DxD) is holding a Summer Innovation and Exploration Series for college student interns from underrepresented groups. The series is on its second day today at Fogarty Innovation and Stanford Byers Center for Biodesign — the two organizations that jointly formed and support DxD. The event debuted last year in an online… […]
  • Clippard releases new series of isolation valves
    Clippard (Cincinnati) has Its Clippard NIV Series media isolation valve — a solenoid-operated device using a flexible diaphragm to isolate the actuation mechanism from the fluid path. Media isolation valves find everyday use in a wide variety of applications. Think uses that require precise, repeatable dispensing of media for analytical instrumentation. Clippard says media isolation… […]
  • Another Medtronic HVAD recall is serious
    A year after Medtronic ceded the LVAD market to Abbott, it has yet another Class I recall involving HeartWare Ventricular Assist Device pumps still implanted in patients. The FDA today designated a Medtronic recall involving the HVADs as Class I, the most serious level. It’s the second Class I recall designation for the HVADs this… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS